Efficacy of Zelnate® DNA Immunostimulant for BRD treatment1

As measured by reduction in mortality


Evaluate the efficacy of Zelnate for BRD treatment as measured by mortality.

Study Procedures

In this study, healthy steers 3-4 months of age were randomly allocated into two groups (n=40 per group). Animals were challenged via intratracheal route (Mannheimia haemolytica) on Day 0. On Day 1 (24 hours later), the animals received intramuscular injection of either Zelnate or a placebo treatment.

Zelnate group: Zelnate (2 mL)

Control group: Placebo (2 mL)

On Day 1, overall morbidity was measured at 67.5%. Clinical examination and lung lesion scoring was performed on dead animals on Days 2-4, and lung lesion scoring on surviving animals was measured on Day 5. Cumulative incidence of death was measured at 11.3% on Day 5.


The chart shows cumulative mortality as observed from the day of challenge (Day 0) to Day 5 post-challenge.

Zelnate vs. Control: Mortality

*Statistically significant reduction (P < 0.05)

Zelnate, as a stand-alone therapy, has been shown to significantly reduce the risk of mortality when administered in the face of clinical BRD.

See the full technical report pdf

1Data on file. Bayer HealthCare Animal Health.

Was this content helpful?